Table 1.

Frequency of mutations in the PIK3CA, AKT1/2/3, PTEN, and KRAS genes in human breast cancers

Tumor subtypePIK3CA catalytic domain (%)PIK3CA other (%)PIK3CA total (%)PTEN (%)AKT1 E17K (%)AKT2/3 E17K (%)KRAS (%)
All human breast tumors, excluding metaplastic and claudin-low cancers73/547 (13.3)44/547 (8.0)117/547 (21.4)2/88 (2.3)6/418 (1.4)0/418 (0)0/418 (0)
Human breast HR+48/232 (20.7)32/232 (13.8)80/232 (34.5)2/58 (3.4)6/232 (2.6)0/232 (0)0/232 (0)
Human breast HER-2+13/75 (17.3)4/75 (5.3)17/75 (22.7)0/10 (0)0/75 (0)0/75 (0)0/75 (0)
Human breast TN12/240 (5.0)8/240 (3.3)20/240 (8.3)0/20 (0)0/111 (0)0/111 (0)0/111 (0)
Human breast claudin-low0/14 (0)0/14 (0)0/14 (0)0/14 (0)0/14 (0)0/14 (0)
Human breast metaplastic4/19 (21.1)5/19 (26.3)9/19 (47.4)1/19 (5.3)0/19 (0)0/19 (0)1/19 (5.3)
  • NOTE: PIK3CA, AKT1/2/3, and PTEN mutation frequency in hormone receptor–positive (HR+), HER-2–positive, and triple-negative (TN) cancers, used herein as a comparator for metaplastic and claudin-low tumors, has been published ( 12).